Clinical development of TLR agonists as adjuvants: "Post-alum adjuvant" candidates may reach beyond their intended purpose

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 813-814

  Green, S J ^a  

^a TripleTree   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR; WART VIRUS VACCINE;

ATHEROSCLEROTIC PLAQUE; DRUG FORMULATION; INNATE IMMUNITY; JOINT STIFFNESS; LETTER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION;

ADJUVANTS, PHARMACEUTIC; ALUM COMPOUNDS; ANIMALS; HUMANS; TECHNOLOGY, PHARMACEUTICAL; TOLL-LIKE RECEPTORS;

EID: 43949128115     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100494     Document Type: Letter

References (4)

1. Schijns, V.E.J.C. & Degen, W.G.J. Vaccine immunopotentiators of the future. Clin. Pharmacol. Ther. 82, 750-755 (2007).
2. Guy, B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
3. Dijkstra, J. et al. Interaction of anti-cholesterol antibodieswith human lipoproteins. J. Immunol. 157, 2006-2013 (1996).
4. Alving, C.R. Antibodies to lipids and liposomes: immunology and safety. J. Liposome Res. 16, 157-162 (2006).